Online inquiry

IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6975MR)

This product GTTS-WQ6975MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets pagA gene. The antibody can be applied in Anthrax research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq WP_000746486.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 45025512
UniProt ID P13423
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6975MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8955MR IVTScrip™ mRNA-Anti-IL1RL2, IL2 fused to diphteria toxin(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL2 fused to diphteria toxin
GTTS-WQ8685MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ4323MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ10005MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KRN-23
GTTS-WQ14312MR IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG-7221
GTTS-WQ4459MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4169MR IVTScrip™ mRNA-Anti-LAG3, BI-754111(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754111
GTTS-WQ9635MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW